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H. pylori Eradication by Four Triple Therapies: 
Randomized Study in Double-Blind
■ ■
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A im : To compare the eradication rates and tolerability of Four 
Triple Therapies administered in naive patients. - 
M ethods: It was a controlled, double-blind study; 238 patients 
(women: 70%, average age: 33.4 years, duodenal ulcer: 57) 
infected by Helicobacter pylori were included. The infection, was 
confirmed on the positivity of urea breath test (UBT) and/or tWo 
among the three following tests: histology, urease test, and culture. 
After randomization, patients received one of the four therapies: 
OAM7, OAMIO, OAC, and RbcMT administered for 7 days with 
usual doses, with the exception of O AM IO  prescribed for 10 days 
with a high dose of metronidazole (500 mg/3xj). Eight to 12 weeks 
after treatment, eradication has been affirmed on the negativity 
of UBT.
Results: The eradication rate of OAM7, OAM IO, OAC, and 
RbcMT was in intention to treat (ITT), (and per protocol -  PP) 
respectively 62.5% (67.3% ), 74.2%J(80.7%), 68T %  .(79 .3^ ), 
and 66% (68.6% ), without a significant difference betweeri’ tfi.e 
groups. The eradication rate of the resistant strains versus 
susceptible ones to metronidazole were respectively in ITT for 
OAM7, OAMIO, and RbcMT: 62.5% vs 46 .i% , 82.3% vs'66.7%', 
and 82.6% vs 50%. The difference was significant [ p -  .02) only 
for RbcMT. The success rate in resistant cases versus susceptible to 
clarithromycin (OAC) was 76.9% Vs 16.7% (p = .61)? Adverse 
events were minimal and more frequently w itb OAC. The 
compliance was complete in 98.4%.
Conclusion : The first-line tritherapies provide eradication rates 
of H. pylori not significantly different arid are well tolerated. 
However, due to a slightly higher efficiency, low  cost, 'k’rii'a 'A  
increasing resistance rate to clarithromycin, the O AM IO  regimen
with a high dose of metronidazole seems more Adapted in Algeria.
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Original and Generic Pantoprazole-Based 
Standard Triple Therapies for the Eradication of
H. pylori Infection in Duodenal Ulcer Patients
B. M. Gyorgy
IX .D istric t  Po lic lin ic, Gastroenterology, Budapest, Hungary
In trod u ction : Generic preparations are bioequivalent with
original brands. However, it is not known .whether their clinical
efficiency is also similar.
A im : To compare the original arid two generic pantoprazole 
preparations1 in eradication of H , pylori infection in duodenal 
ulcer patients. ,
M eth od s: Seventy-six endoscopically (Fujinon EC250WL Video 
system) confirmed active duodenal ulcer patients were enrolled in
■Ain lif 'nofjffriWw.>> elrh
’Original drug: Controloc® Nycorped, Germany; G1; Nolpaza®, Krka, 
Slovenia, G2: Pantoprazole Ratiopharm®, Ratiopharm, Germany.
an open, prospective, randomized study. H. pylori infection was 
confirmed from antrum and corpus samples by histology (modified 
Giemsa stain), immunohistology and, if needed, FISH. The patients 
were assigned to a 7-day standard regimen containing 2 x 40 mg 
pantoprazole, 2 x  1000 mg amoxicillin, and 2 x 500 mg clarith­
romycin; 24 cases received the original, while 26 and 26 patients, 
respectively, were given genericpantoprazoles (group G1 and G2). 
The eradication of the infection was controlled by l3C-urea breath 
test performed 6 weeks after treatment.
Results: The eradication rate on an intention-to-treat basis was 
of 70% (95%  confidant« fritbrval, Cl: 51.2-90.4%) in patients 
receiving the original pantoprazole, 73.9% (54.5-93.3) in group 1 
{p =  .63), and 77.8% (61.2-88.3) in group 2 (p =  .57). Per-protocol 
rates o f eradication were 73.9% (54.5-93.3) in the original group, 
86.9% (72.0-99.8) in the G1 grotip (p = .26), and 84.0% (77.2- 
92$  i f f B T p > 1& q j№ 3 9 )r, P f f .W lJ  I. ,
Conclusions: The clinical efficiency of the original and generic 
pantoprazoles in'the eradication of H. Pylori infection in duodenal 
ulcer is similar.
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Infection w ith .Helicobacter pylori results in the lesions of mucous 
barrier o f stomach (M BS) and enhances the aggressive properties 
of gastric juice.
The aim Was to improve-the effectiveness of peptic duodenal 
ulcer (PDU) therapy by introducing rebamipide into the therapy 
complexes. k
Forty-tw o PDU HP-associated patients w ere under the 
observation. The size of ulcerative lesions was 7.2 ±2 .1  mm. 
Mucus-producing function of MBS was evaluated by the content 
of N-acetylneuraminic add (N A N A ) and fucose in the blood 
serum and by their excretion w ith urine.
The patients were divided into two groups: I  (n = 22) -  
pantoprazole-clarithromycin-amoxicillln -  anti-/T. pylori therapy 
10 days; II (n = 22) additionally took rebamipide 300 mg/day for 
28 days.
Clinical and endoscopic PDU remission in 28 days was recorded 
in21 (95.5% ) patients in group I and 22 (100% ) patients in group
II, while H. pylori eradication in 19 (86.4% ) patients in group I and 
21 (95.5% ) patients in group II.
After the therapy had been completed the N A N A  concentration 
in group I reduced 1.15 times; group n  1.3 times (p < .001). N ANA 
excretion with urine in group I decreased 1.1 times; group n 1.3 
times (p < .05). Due to the anti-H. pylori therapy and rebamipide, 
the N A N A  excretion with urine was 1.2 times (p < .05) lower th'an 
that in group I  The blood serum concentration of, fucose bound 
with proteins In ’giOup I patients increased 1.6 times (p < .001). 
The similar changes were detected when studying fqcose excretion 
with Urine. -iv,'.., ■
The administration of rebamipide in combination with anti- 
H. pylori therapy increases the therapeutic effectiveness by 
enhancing duodenal mucotis barrier resistance.
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